Zeo ScientifiX, Inc. (ZEOX) Financial Statements (2025 and earlier)
Company Profile
Business Address |
3321 COLLEGE AVENUE DAVIE, FL 33314 |
State of Incorp. | NV |
Fiscal Year End | October 31 |
Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
7/31/2024 MRQ | 1/31/2024 MRQ | 10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | 10/31/2019 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 1,172 | 1,756 | 3,753 | 109 | 591 | 133 | |||
Cash and cash equivalents | 1,172 | 1,756 | 3,753 | 109 | 591 | 133 | |||
Receivables | 89 | 30 | 191 | 104 | 29 | 26 | |||
Inventory, net of allowances, customer advances and progress billings | 316 | 310 | 249 | 235 | 147 | 78 | |||
Inventory | 316 | 310 | 249 | 235 | 147 | 78 | |||
Prepaid expense | 315 | 106 | 173 | 70 | 79 | 121 | |||
Total current assets: | 1,892 | 2,202 | 4,366 | 517 | 846 | 358 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 105 | ||||||||
Property, plant and equipment | 533 | 573 | 1,684 | 1,113 | 365 | 263 | |||
Other undisclosed noncurrent assets | 7 | 7 | 151 | 302 | 18 | 5 | |||
Total noncurrent assets: | 540 | 580 | 1,834 | 1,416 | 488 | 268 | |||
TOTAL ASSETS: | 2,432 | 2,782 | 6,201 | 1,933 | 1,334 | 626 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 2,219 | 2,612 | 2,379 | 1,873 | 766 | 552 | |||
Accrued liabilities | 782 | 748 | 758 | 1,542 | 1,156 | 853 | |||
Other undisclosed accounts payable and accrued liabilities | 1,437 | 1,864 | 1,621 | 331 | (391) | (300) | |||
Debt | 673 | 680 | 144 | 140 | 233 | 432 | |||
Disposal group, including discontinued operation | 126 | 126 | 126 | ||||||
Due to related parties | ✕ | ✕ | ✕ | 221 | 221 | 221 | |||
Other undisclosed current liabilities | 1,031 | 718 | 1,320 | 1,766 | 1,194 | 925 | |||
Total current liabilities: | 3,923 | 4,010 | 4,063 | 4,126 | 2,540 | 2,036 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation, including: | 13 | 220 | 332 | 186 | 153 | ||||
Long-term debt, excluding current maturities | 332 | ||||||||
Finance lease, liability | 13 | 220 | 119 | ||||||
Other undisclosed long-term debt and lease obligation | 153 | ||||||||
Liabilities, other than long-term debt | 29 | ||||||||
Operating lease, liability | 29 | 67 | |||||||
Other undisclosed noncurrent liabilities | 17 | 140 | (67) | ||||||
Total noncurrent liabilities: | 17 | 13 | 249 | 472 | 186 | 153 | |||
Total liabilities: | 3,940 | 4,023 | 4,312 | 4,599 | 2,726 | 2,189 | |||
Equity | |||||||||
Equity, attributable to parent | (1,508) | (1,241) | 1,889 | (2,666) | (1,392) | (1,563) | |||
Common stock | 6 | 7 | 1,479 | 1,132 | 940 | 503 | |||
Additional paid in capital | 57,034 | 56,260 | 50,931 | 37,827 | 26,536 | 14,220 | |||
Accumulated deficit | (58,548) | (57,508) | (50,521) | (41,625) | (28,868) | (16,285) | |||
Total equity: | (1,508) | (1,241) | 1,889 | (2,666) | (1,392) | (1,563) | |||
TOTAL LIABILITIES AND EQUITY: | 2,432 | 2,782 | 6,201 | 1,933 | 1,334 | 626 |
Income Statement (P&L) ($ in thousands)
7/31/2024 TTM | 1/31/2024 TTM | 10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | 10/31/2019 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 4,642 | 4,558 | 6,491 | 5,597 | 3,056 | 1,702 | ||
Cost of revenue | (562) | (508) | (754) | (548) | (399) | (301) | ||
Gross profit: | 4,080 | 4,051 | 5,737 | 5,050 | 2,657 | 1,401 | ||
Operating expenses | (9,832) | (10,818) | (14,580) | (17,794) | (15,095) | (3,178) | ||
Operating loss: | (5,753) | (6,767) | (8,843) | (12,744) | (12,438) | (1,776) | ||
Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (10) | 250 | 25 | 33 | 85 | |||
Interest and debt expense | (397) | (431) | (398) | (178) | (47) | |||
Other undisclosed loss from continuing operations before equity method investments, income taxes | (10) | |||||||
Loss from continuing operations before equity method investments, income taxes: | (6,160) | (7,208) | (8,992) | (12,719) | (12,583) | (1,738) | ||
Other undisclosed income (loss) from continuing operations before income taxes | 95 | (38) | 0 | |||||
Loss from continuing operations before income taxes: | (6,160) | (7,208) | (8,897) | (12,757) | (12,583) | (1,738) | ||
Income tax benefit | 3,215 | 3,168 | 205 | |||||
Loss from continuing operations: | (6,160) | (7,208) | (8,897) | (9,541) | (9,415) | (1,534) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (9,541) | (9,415) | (1,534) | |
Other undisclosed net income (loss) | 198 | (3,215) | (3,168) | (205) | ||||
Net loss: | (5,962) | (7,208) | (8,897) | (12,757) | (12,583) | (1,738) | ||
Net income attributable to noncontrolling interest | 1 | |||||||
Other undisclosed net income attributable to parent | 222 | 222 | ||||||
Net loss available to common stockholders, diluted: | (5,740) | (6,987) | (8,897) | (12,757) | (12,583) | (1,737) |
Comprehensive Income ($ in thousands)
7/31/2024 TTM | 1/31/2024 TTM | 10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | 10/31/2019 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (5,962) | (7,208) | (8,897) | (12,757) | (12,583) | (1,738) | ||
Comprehensive loss: | (5,962) | (7,208) | (8,897) | (12,757) | (12,583) | (1,738) | ||
Comprehensive income, net of tax, attributable to noncontrolling interest | 1 | |||||||
Comprehensive loss, net of tax, attributable to parent: | (5,962) | (7,208) | (8,897) | (12,757) | (12,583) | (1,737) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.